Nuance Pharma Announces Ensifentrine Meets Primary Endpoint in Phase 3 ENHANCE-CHINA Trial for COPD
Statistically significant improvements in lung functionConsistent trends of quality of life and exacerbation rate reduction as ENHANCE-1/2Well tolerated safety profileNDA submission planned for 2H 2025
SHANGHAI, May 16, 2025 /PRNewswire/ -- Nuance Pharma ("Nuance") today announces its top-line Phase 3 ENHANCE-CHINA (NCT05743075) trial results evaluating nebulized ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease ("COPD"). The ENHANCE-CHINA trial has successfully met its primary endpoint, as well as secondary endpoints demonstrating improvements in lung function.
The investigational study drug, ensifentrine is a first-in-class selective dual inhibitor of phosphodiesterase 3 and 4 ("PDE3; PDE4") that combines bronchodilator and non-steroidal anti-inflammatory effects in one molecule, delivered directly to the lungs through a standard jet nebulizer without the need for high inspiratory flow rates or complex hand-breath coordination.
Highlights
- Study population (n = 526 randomized):
Subject demographics and disease characteristics were well balanced between treatment groups
Approximately 46% of subjects received background COPD therapy, either a long-acting muscarinic antagonist ("LAMA") or a long-acting beta-agonist ("LABA"). Additionally, approximately 38% of all subjects received inhaled corticosteroids ("ICS") with concomitant LABA.
- Primary endpoint met (FEV1 AUC 0-12hr):
Placebo corrected, change from baseline in average FEV1 area under the curve 0-12 hours post dose at week 12 was 110 mL (p<0.0001) for ensifentrine
Statistically significant and clinically meaningful improvements with ensifentrine demonstrated across key subgroups including age, smoking status, COPD severity, background medication, ICS use, chronic bronchitis, FEV1 reversibility
- Secondary endpoints of lung function:
Placebo corrected, increase in peak FEV1 of 174 mL (p<0.0001) at week 12
Placebo corrected, increase in morning trough FEV1 of 36 ml (p=0.0533) and evening trough FEV1 of 65 ml (p=0.0038) at week 12, confirming twice daily dosing regimen.
Placebo corrected, increase in average FEV1 of 162 ml (p<0.0001) 0-4 hours post dose and 77 mL (p=0.0003) 6-12 hours post dose at week 12
- COPD symptoms and quality of life (QoL):
Clinically meaningful improvements in dyspnea as measured by Transition Dyspnea Index (TDI) in the ensifentrine group were observed at all weeks (6, 12 and 24) with a statistically significant improvement of 0.8 unit compared to placebo at week 24.
Quality of Life (QoL) as measured by St George's Respiratory Questionnaire (SGRQ) Total Score in the ensifentrine group improved from baseline to greater than the MCID of -4 units with a significant improvement of -2.9 units compared to placebo at week 24.
Daily symptoms as measured by Evaluating Respiratory Symptoms (E-RS) Total Score in ensifentrine group showed improvement from baseline as early as 6 weeks and continued improvement at 12 and 24 weeks, numerically exceeding placebo at each measurement.
- Exacerbation rate reduced
Subjects receiving ensifentrine demonstrated a 28% reduction in the rate of moderate/severe COPD exacerbations over 24 weeks compared to those receiving placebo (RR = 0.72, 95% CI: (0.43, 1.22))
Treatment with ensifentrine significantly decreased the risk of a moderate/severe exacerbation as measured by time to first exacerbation when compared with placebo by 25% (HR = 0.75, 95% CI: (0.44, 1.28))
- Favorable safety profile:
Ensifentrine was well-tolerated with treatment related AE incidence similar to placebo
Mark Lotter, founder and Chief Executive Officer of Nuance Pharma, said:"We are very pleased by the successful outcome of our Phase 3 ENHANCE-CHINA study, bringining us another step closer to providing a much needed novel therapy for COPD patients in China. These promising results demonstrate ensifentrine's strength as a first-in-class bronchodilator and non-steroidal anti-inflammatory therapy for COPD, as an advance to existing treatment options. We plan to submit a New Drug Application to the China NMPA in the second half of 2025. We would like to thank all the patients and investigators for their participation in the ENHANCE-CHINA program. "
Charlie Chen, Chief Operating Officer of Nuance Pharma added:"The totality of ENHANCE data including improvements in lung function, symptoms, quality of life measure and reduction in exacerbations, coupled with favorable safety profile, support our belief that ensifentrine will change the treatment paradigm for COPD. Following our ongoing early access programs in Hainan BoAo and Greater Bay Area, as well as regulatory approval in Macau, we look forward to bringing this medicine to patients in Greater China."
David Zaccardelli, Pharm. D., President and Chief Executive Officer of Verona Pharma, said:"we look forward to Nuance Pharma's continued progress and having Ohtuvayre® available for the millions of symptomatic patients needing additional treatment."
Nuance Pharma plans to release additional information from ENHANCE-CHINA at upcoming scientific conferences.
In Feb 2025, the Pharmaceutical Administration Bureau Macau approved Ohtuvayre™ (ensifentrine) for the maintenance treatment of COPD in adult patients. In Nov 2024, Nuance Pharma launched Ohtuvayre™ in China's Hainan Boao Pilot Zone through early access program. In Sep 2024, Nuance Pharma completed recruitment for ENHANCE-CHINA, the phase 3 clinical trial of Ohtuvayre™ (ensifentrine) for the maintenance treatment of COPD.
In June 2024, Nuance Pharma's global partner Verona Pharma plc (Nasdaq: VRNA), announced the US Food and Drug Administration ("FDA") approved Ohtuvayre™ (ensifentrine) for the maintenance treatment of COPD in adult patients.
In 2021, Nuance Pharma entered into an agreement with Verona Pharma for the exclusive rights to develop and commercialize Ohtuvayre™ (ensifentrine) in Greater China (mainland China, Hong Kong, Macau and Taiwan).
About Ohtuvayre™ (ensifentrine)Ohtuvayre™ is the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Verona has evaluated nebulized Ohtuvayre™ in its Phase 3 clinical program ENHANCE ("Ensifentrine as a Novel inHAled Nebulized COPD thErapy") for COPD maintenance treatment. Ohtuvayre™ met the primary endpoint in both ENHANCE-1 and ENHANCE-2, demonstrating statistically significant and clinically meaningful improvements in lung function.
About the ENHANCE-CHINA programThe randomized, double-blind, placebo-controlled study evaluate the efficacy and safety of nebulized ensifentrine as monotherapy and added onto a single bronchodilator, either a LAMA or a LABA, compared to placebo, and subjects may receive ICS.
Patient Population: 526 moderate to severe, symptomatic, COPD patients at 46 sites in China.
Dose/Duration: subjects were randomized to receive a 3mg nebulized dose of ensifentrine or nebulized placebo twice daily for 24 weeks
Primary Endpoint: Improvement in lung function with ensifentrine as measured by average FEV1 AUC 0-12 hours post dose at week 12.
Secondary Endpoints: lung function endpoints including peak and morning trough FEV1, COPD symptoms and health related quality of life through 24 weeks via SGRQ and E-RS, and exacerbation at 24 weeks, and others
Safety: Assessed over 24 weeks
Further information about ENHANCE-CHINA program can be found at www.clinicaltrials.gov (NCT05743075)
About Verona PharmaVerona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. Ohtuvayre™ (ensifentrine) is the Company's first commercial product and the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Ohtuvayre™ (ensifentrine) has potential applications in non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com.
About Nuance PharmaNuance Pharma is an innovation focused biopharmaceutical company, with both late-stage clinical pipeline and commercial stage asset portfolio. Focusing on specialty care, Nuance has established a differentiated combination of commercialized assets and innovative pipeline across respiratory, pain management, emergency care and iron deficiency anemia. With the mission to address critical unmet medical needs in Asia Pacific, Nuance deploys the Dual Wheel model that develops a global leading innovative pipeline, while maintaining a self-sustainable commercial operation in both China and Asia as a region. For more information, please visit www.nuancepharma.com.
Forward-looking StatementsThis news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.
View original content:https://www.prnewswire.com/apac/news-releases/nuance-pharma-announces-ensifentrine-meets-primary-endpoint-in-phase-3-enhance-china-trial-for-copd-302457563.html
SOURCE Nuance Pharma Limited
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Air quality alert issued for all of Minnesota due to wildfire smoke from Canada
The Brief The Minnesota Pollution Control Agency (MPCA) has issued an air quality alert for all of Minnesota due to wildfire smoke from Canada. The alert takes effect at 11 p.m. Saturday and goes until 11 p.m. on Sunday. The air quality index is in the orange category, which means the air will be unhealthy for sensitive groups. (FOX 9) - The Minnesota Pollution Control Agency (MPCA) has issued an air quality alert for all of Minnesota due to the continuing wildfires in Canada. What they're saying MPCA issued an air quality alert as heavy surface wildfire smoke from Canada is expected to follow a cold front into Minnesota, affecting the whole state. The alert will be in place from 11 p.m. Saturday until 11 p.m. Sunday. MPCA says the smoke is expected to move across the state from west to east late Saturday night, then clear out west to east by Sunday afternoon or evening. The air quality index is expected to reach the orange category, which is unhealthy for sensitive groups. What to expect Minnesotans can expect to see a hazy sky, and smell smoke in the air, MPCA says. For sensitive groups, like people with asthma, COPD, heart disease, children, older adults and pregnant people, being outside during the alert could impact their health. What you can do MPCA says to reduce activities that contribute to poor air quality, like fires, reducing vehicle trips and vehicle idling as much as possible. To keep up to date on current air quality conditions, click here. The Source A press release from the Minnesota Pollution Control Agency (MPCA).
Yahoo
8 hours ago
- Yahoo
After October 7, 2023: Israel's smoking rates rise, worsening COPD risks
Smoking rates are growing among young Israelis, said Fridlender, an internationally renowned researcher of neutrophil white blood cells of the immune system, especially their role in lung cancer. A quarter to a third of all smokers suffer from chronic obstructive pulmonary disease – also known as emphysema – which is an incurable lung disease causing restricted airflow and breathing problems that can make sufferers feel like they are trying to breathe underwater. But few COPD patients have ever heard of it, according to Prof. Zvi Fridlender, founding director and senior physician of the internal medicine department at the Lung Institute of Hadassah-University Medical Center in Jerusalem's Ein Kerem. He is also chairman of the Israel Association of Pulmonology. COPD is the fourth leading cause of death worldwide, responsible for almost four million annually, or 5% of the total. Tobacco smoking and second- and third-hand smoking (exposure to other's smoke or toxins on rugs, curtains, and furniture) accounts for over 70% of COPD cases in high-income countries, with symptoms including coughing, sometimes with phlegm, difficulty breathing, wheezing, and tiredness. Many sufferers can't even walk a hundred meters and have to be constantly attached to oxygen tanks. Patients are at higher risk of other health problems such as lung cancer, lung infections, heart problems, weak muscles, brittle bones, and depression and anxiety. 'We have plenty of laws. Anyone who is caught smoking in public places should be getting a NIS 1,000 fine, but they aren't caught,' Fridlender told The Jerusalem Post. 'The laws aren't enforced by the authorities – the police and the municipalities. There are few effective information campaigns, and taxes on tobacco – cigarettes, rolling tobacco, and electronic cigarettes – must be very high to deter young smokers,' he said. 'While in other countries like the UK, once a law is passed, it is usually honored. Here it is more like a recommendation that is very often ignored.' ANTI-SMOKING activists are furious at Sharon Kedmi, chairman of the Israel Aviation Authority, for canceling the prohibition of smoking rooms in the airports. This violated the authority's commitment to a court in a class action suit filed by Amos Hausner, lead lawyer for the Israel Association for the Prevention of Smoking. The longtime anti-tobacco attorney is currently demanding that the courts prohibit smoking on balconies of apartment buildings or other locations that exposes non-smokers to their neighbors' smoke. In California, 101 local authorities have already completely banned smoking in multi-unit homes, and since 2018, it has been totally prohibited in all federal multi-unit buildings. Smoking rates are growing among young Israelis, said Fridlender, an internationally renowned researcher of neutrophil white blood cells of the immune system, especially their role in lung cancer. He has also been a member of the international body that sets guidelines for the treatment of COPD. 'While smoking rates have significantly declined in the US, Europe, and elsewhere, it has increased in Israel since the Iron Swords War began on October 7, 2023,' he said. Prof. Neville Berkman, who heads the lung institute at Hadassah, added that it's not only smokers who are at health risk. 'People who themselves don't light up think they're safe, but many of them are exposed to lethal tobacco smoke by inhaling it from smokers in the family, at work, and in public spaces,' he said. Electronic cigarettes (e-cigs) also cause lung cancer, which is the main cause of death from cancers in Israel, Berkman said, adding that people who start smoking them, especially young people, tend to move on to smoking regular cigarettes. 'There is behavioral addiction, not just a physical one. They are used to having something in their mouths. Younger smokers may do it to show off, to show they are grown up,' he said. 'Smoking should be recognized by society as an unacceptable practice. Religious Jews who don't smoke on Shabbat (although some use nicotine patches then) prove that it's also behavioral, because they can stop one day a week,' the lung institute's head said. 'The rabbis must tell them that smoking – causing harm to your own body and the health of others – is forbidden according to Jewish law.' SMOKERS WHO cough or have other symptoms can ask for a low-radiation-dose CT scan every year, said Berkman. 'It's in the basket of health services provided by the public health funds, which recognize the fact that treating their members for lung cancer and COPD is more expensive.' The last decade has seen significant improvement in treatment of lung cancer, he continued. 'There are biological therapies – pills and injections – that increase survival rates, but these are not pleasant to undergo, as they have side effects,' he stressed. Biological therapies for lung cancer, also known as targeted therapies and immunotherapies, are treatments that use substances produced by living organisms or are designed to target and destroy cancer cells. Immunotherapy works by boosting the immune system's ability to recognize and destroy cancer cells, either by directly attacking them or by helping other immune cells do so. Drugs that alter the immune system can also be effective. These therapies aim to enhance the body's natural defenses against cancer, block cancer growth, or prevent the spread of cancer. 'The earlier the stage of the disease, the better. If the cancer is advanced, radiation therapy, chemotherapy, and other treatments are available, but if they also have COPD, most can't undergo surgery to remove the tumor,' Berkman said. The most important thing is prevention – by not starting to smoke in the first place, he said, adding that if they do start, there are free cessation courses from their health fund, behavioral therapy, phone apps, and drugs that reduce the urge to smoke – 'and the Health Ministry offers a telephone support system.' THE 2024 report on smoking issued by the Health Ministry found that one in five adult Israelis smokes, and the Israeli rate is significantly higher than the global average, and said that E-cigs are a leading smoking product among youth. Quitting smoking here is occurring at a rate 50% lower than the OECD average. Although the ministry has finally approved regulations for putting graphic health warnings on smoking products and barring tax-free status for tobacco at airports – two decades after Israel committed itself to doing so under the World Health Organization's Framework Convention on Tobacco Control – it is giving companies a year or two to implement them. An in-depth survey conducted with youth for the ministry shows that the electronic cigarette is the first product tried by about 53% of all those experimenting with products. It was also found that very high numbers of youth use smoking products with added flavors – 88% for hookahs, 82% for electronic cigarettes, and 45% for regular cigarettes and rolling tobacco. The first survey of its kind, conducted among young people in haredi (ultra-Orthodox) society, shows high rates of experimenting with smoking products: 54% in their yeshivot for teens and 80% among haredi teenagers who drop out of religious studies. The latest Smoking Report shows that during the past year, 82 local and regional authorities and councils also reported on activity under the Smoking Prevention Law in Public Places – but more than 65% of local authorities don't report to the ministry or enforce the law, and no government action is taking against them. Sign up for the Health & Wellness newsletter >>
CNN
12 hours ago
- CNN
Why men with broken heart syndrome are more likely to die, according to experts
Get inspired by a weekly roundup on living well, made simple. Sign up for CNN's Life, But Better newsletter for information and tools designed to improve your well-being. Source: CNN A 59-year-old man arrived at the Peking University First Hospital in Beijing for a procedure when he started having severe chest pain and shortness of breath. Four months earlier, he had cancerous tumors removed from his bladder. Around his family, he tried his best to appear strong and avoided discussions of his health. Privately, his severe anxiety over the possibility of a cancer recurrence kept him awake at night. Doctors said the man was experiencing takotsubo cardiomyopathy — also known as broken heart syndrome, as documented in a 2021 case study. The rare stress-induced heart condition has been observed primarily in women, but a study published in the Journal of the American Heart Association in May found that the illness may be more deadly for the men who get it. Thought to be caused by extreme emotional or physical events — such as learning about the death of a loved one, winning the lottery or lifting a heavy sofa — takotsubo cardiomyopathy, or TC, occurs when the heart muscle is flooded with stress hormones, causing part of it to 'freeze' in place. As the heart struggles to properly pump blood, symptoms resemble those of a heart attack, including chest pain, heart palpitations and irregular heartbeat. The new study analyzed data from nearly 200,000 patients hospitalized for TC in the United States between 2016 and 2020. While women accounted for 83% of the cases, men were more than twice as likely to die from the condition — with a mortality rate of 11.2%. 'The differences between men and women are a very striking finding,' said study coauthor Dr. Mohammad Reza Movahed, a clinical professor of medicine at the University of Arizona in Tucson. 'It raises a new, interesting question that should really be studied.' Similar to differences between men's and women's cardiovascular health more generally, the discrepancies in TC death rates are not well understood, Movahed said, especially because they counter trends in other heart diseases. It's widely theorized, however, that differences in hormone levels play a role. Stressful situations trigger the adrenal glands to release our fight-or-flight hormones, called catecholamines. They are meant to increase our blood pressure and raise our heart rate, but extreme levels can temporarily 'stun' cells in the heart's tissue, leading to TC, Movahed explained. Men are thought to produce more catecholamines during stressful situations compared with women, possibly leading men to present with more severe cases of TC, he suggested. Estrogen, a sex hormone produced at higher levels in women, may also have a protective effect on the cardiovascular system, making it easier to manage an extreme influx of catecholamines and reducing the risk of severe complications from TC, said Dr. Louis Vincent, a noninvasive-cardiology research fellow at the University of Miami, who coauthored a similar, multiyear study investigating discrepancies in men and women who had TC. Vincent was not involved in the new study. Beyond biological differences, social factors may play a role as well. 'Most (physicians) know about takotsubo, but they may think of it as a disease just affecting women, so the diagnosis might be overlooked in men,' said Dr. Deepak Bhatt, a cardiologist and the director of Mount Sinai Fuster Heart Hospital who was not involved in the study. 'With misdiagnosis, care is delayed, and that can sometimes lead to worse outcomes.' Men may also seek care at a later stage of illness, believing that their symptoms are manageable or may pass, said Dr. Alejandro Lemor, an assistant professor of interventional cardiology at the University of Mississippi Medical Center who was also not involved in the study. Deadly complications from TC include blood clots, stroke, cardiac arrest and heart failure, Lemor said. If the condition is caught early, medications can reduce the risk of having these complications, restore proper heart function and allow for full recovery within weeks, he added. Movahed's team was able to factor for important variables like age, race, income, chronic lung disease, hypertension and diabetes in the findings. However, there was no patient data on other comorbid diseases, such as a history of stroke or the presence of a Covid-19 infection, Vincent said. Additionally, the new study included in-patient diagnostic data only for those hospitalized with TC, so those who received outpatient care or died later from complications outside the hospital were likely not counted in the analysis, Movahed noted. To establish a firmer explanation for the differences in mortality rates between men and women and further test treatment methods, a more detailed dataset would be needed, Vincent said. 'People should be aware in studies like this, we're presenting findings that are based on diagnostic codes, and we're not looking at patient procedures or lab results,' Vincent said. 'But it's powerful in the sense that it lets us look at large populations and look at trends. And I think that this trend of a higher mortality in men is worth taking a deeper look into.' Sudden, severe chest pain or shortness of breath should always be treated as a medical emergency, warned Bhatt, who is also a professor of cardiovascular medicine at the Icahn School of Medicine at Mount Sinai in New York City. 'It's not a time to tough it out at home or get on the internet to figure it out. … Don't try to track down your primary care provider. Call emergency services,' Bhatt said. 'Time matters. By winning those few hours, you could save yourself irreparable damage to your heart.' Symptoms following physical stressors — a common cause of TC in men — should not be ignored, Movahed said, especially preceding medical events such as asthma attacks, seizures or complications from drug use. And while TC is caused by sudden stress, Bhatt said that managing chronic stress with daily meditation or exercise can lead to better cardiovascular health overall while giving you routines to fall back on in unexpected situations. See Full Web Article
